Partnerships between public health entities and private managed care systems have proven crucial for tracking public health trends. Now that the Centers for Disease Control and Prevention (CDC) is preparing to go live with its National Bioterror Syndromic Surveillance Demonstration Project, MCOs continue to shape the country's ability to recognize and respond to health threats, including ones posed by biological, chemical and radiological agents.
The senior vice president of health services and chief medical officer at Independence Blue Cross in Philadelphia discusses the spotlight that the COVID-19 pandemic put on behavioral health and Independence's integration of behavioral health into its coverage and care management in this month's episode of “What's on Your Mind?" podcast.
Listen
What Reimbursable Remote Care Through New CMS CPT Codes Means For Patients
March 1st 2023Briana Contreras, an editor of Managed Healthcare Executive, chats with Bronwyn Spira, CEO and founder of Force Therapeutics, in this week's episode about CMS' new CPT codes that were introduced in 2022.
Listen
FDA Updates for the Week of March 20, 2023
March 25th 2023FDA approvals this week include: novel treatment for invasive candidiasis, an accelerated approval to Zynyz for Merkel cell carcinoma, the high-concentration Humira biosimilar Hyrimoz, and extension of Evkeeza’s indication to include young children. The agency also issued two complete responses this week: for Incyte’s extended-release Jakafi and for AbbVie’s Parkinson’s therapy.
Read More
Tis Full and Very, Very Expensive: the 2023 Specialty Drug Pipeline | AMCP 2023
March 24th 2023Specialty drugs are expected to comprise 80% of the FDA approvals this year. Among them are gene therapies for hemophilia A and Duchenne muscular dystrophy priced at between $2 million and $3 million.
Read More
2 Clarke Drive
Cranbury, NJ 08512